US20020098238A1 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
US20020098238A1
US20020098238A1 US10054490 US5449002A US20020098238A1 US 20020098238 A1 US20020098238 A1 US 20020098238A1 US 10054490 US10054490 US 10054490 US 5449002 A US5449002 A US 5449002A US 20020098238 A1 US20020098238 A1 US 20020098238A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
polylactide
according
weight
solution
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10054490
Inventor
Walter Prikoszovich
Original Assignee
Walter Prikoszovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08Lactones or lactides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/88Post-polymerisation treatment
    • C08G63/90Purification; Drying

Abstract

A polylactide in a purified state, which meets the requirements of
the color strengths of reference solutions B2-B9 of the brown colour test of the European Pharmacopoeia, 2nd Edition (1980) part I, Section V, 6.2 and
containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm.
The polylactide is especially suitable for use as microparticles or implants, and contains preferably a hydrophilic drug, like octreotide or a lipophilic drug like bromocriptine.

Description

  • This invention relates to polylactides in a purified state, to the method of their purification and to pharmaceutical compositions comprising the purified polylactides. [0001]
  • The European Patent Application No. 0270987 A2 describes polylactides, e.g. polylactide-co-glycolides, which have been prepared by condensation of lactic acid and glycolic acid or preferably by polymerisation of lactide and glycolide in the presence of a catalyst, e.g. tin di-(2-ethyl hexanoate), also known as tin octoate or tin octanoate. [0002]
  • The polylactides are purified by dissolving them in a solvent, which is not or is only partially miscible with water, e.g. methylene chloride, and washing the solution with an aqueous solution of an acid, e.g. HCl or of a metal ion complexing agent e.g. EDTA, after which the catalyst metal cation or its complex is transferred to the aqueous solution, in which it is better soluble. [0003]
  • However, after separation and isolation of the organic solvent layer and the precipitation of the polylactide from it e.g. by mixing the layer with an organic solvent, e.g. petrol ether or an alcohol, e.g. methanol, which dislodges the polylactide from the solution, the precipitated polylactide still contains a certain amount of the catalyst metal cation—about 2 ppm—and additionally the catalyst anion, e.g. in acid form. Further the polylactide contains a certain amount of brown coloured decomposition by-products which have been formed in the polymer preparation process, especially under the influence of the catalyst. [0004]
  • Since polylactides, e.g. polylactide-co-glycolides, are preferably used as matrices for drug compounds e.g. in implants or microparticles, which are administered parenterally, the remaining impurities can give rise to local irritation reactions of the body tissue and, e.g. depending on the catalyst type, to an instability of the matrix and thus possibly to an accelerated drug compound release. The brown impurities and the catalyst should thus preferably be removed as good as possible. [0005]
  • Catalyst-free polylactides on the basis of the condensation of lactid acid and optionally glycolic acid are known, but have low molecular weights of about 2000 to 4000. [0006]
  • Polylactides of a higher molecular weight are preferred and can only be made in the presence of a catalyst. [0007]
  • According to the European Patent No 0026599 B1 lactic acid and glycolic acid were reacted in the presence of a strong acid ion-exchange resin as a catalyst, which after the reaction could be removed from the copolymer product by filtering the molten reaction mixture or by cooling the reaction mixture, dissolving the copolymer in an organic solvent in which the ion-exchange resin is insoluble, filtering the solution and removing the organic solvent after which a copolymer was obtained from which the solid phase catalyst was removed to a substantially extent. [0008]
  • However, by this method only polylactides were obtained having a molecular weight of from about 6000 to 35000. [0009]
  • Polylactides, e.g. polylactide-co-glycolides, having a broader molecular weight range than up to 35000 are preferably made by using lactide and optionally e.g. glycolide as monomers, but are polymerised in the presence of a metal catalyst, which reaction type, as has been discussed before, leads to a considerable contamination of the reaction product. [0010]
  • We have found now, that polylactides, e.g. polylactide-co-glycolides, especially those prepared from lactide and glycolide as monomers, can be obtained in a better purified state. [0011]
  • The invention provides a polylactide in a purified state which meets the requirements of [0012]
  • the colour strengths of reference solutions B[0013] 2-B9 of the brown colour test of the European Pharmacopoeia, 2nd Edition (1980), part I, Section V, 6.2. and
  • containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm. [0014]
  • The polylactide preferably has the reduced colour strengths of the reference solutions B[0015] 4-B9, especially of reference solution B9. The colour of a reference solution B9 indicates that the polylactide is an off-white or colourless product.
  • The polylactides which are preferably prepared contain particularly bivalent metal ions, like Zn[0016] ++ and especially Sn++.
  • For the determination of the tin amount, the polymer is decomposed under high pressure with a mixture of hydrochloric acid and nitric acid. The precipitation and concentration of tin from that mixture occurs on a membrane filter and the measurement of the metal amount is carried out by energy dispersive X-ray fluorescence (EDXRF), as described by H. D. Seltner, H. R. Lindner and B. Schreiber, Intern. J. Environ. Anal. Chem., 1981, Vol. 10, pp. 7-12 supplemented with a reference graphite furnace atomic absorption spectrometry method, as discussed on the 6th Colloquim Atomspektrometrische Spurenanalytik, Apr. 8-12, 1991 in Konstanz, Germany, Authors: H. Seltner, G. Hermann and C. Heppler. [0017]
  • According to the invention the concentration of Sn[0018] ++ in the purified polyactide of the invention is preferably at most 1.5 ppm, particularly at most
  • 1 ppm; the catalyst anion is preferably ethyl-hexanoate, which is in the purified polylactide of the invention preferably present in a concentration of at most 0.5% by weight of the polylactide. [0019]
  • The purified polylactide preferably contains apart from its lactide units further structural units e.g. such as described in the european Patent Application No 0270987, second passage on page 4, of which the glycolide unit is the preferred unit since, depending on its monomer ratio in the polymer chain, it can shorten the decomposition period of the polymer in the body and thus accelerate the drug compound release time. The glycolide unit is, as is known, the most frequently used additional unit in polylactides. [0020]
  • The monomer molar ratio's of the lactide/glycolide units in the purified polymers according to the invention are preferably 100-25/0-75, particularly 75-25/25-75, especially 60-40/40-60, more especially 55-45/45-55, e.g. 55-50/45-50. [0021]
  • It is known that the polymerisation reaction of monomers like lactide and glycolide is preferably carried out in the presence of a compound having one or more hydroxylgroups, which functions as a starter in building up a linear polymer chain. Known starters are e.g. lactic acid and glycolid acid. Other hydroxyl group containing compounds can also be used, e.g. alcohols. The starters are in fact used to control the chain length of the polylactides. A smaller amount of starting hydroxyl compound leads to longer chains than greater amounts. Excellent regulators are polyols, e.g. those described in the UK Patent Application GB 2.145.422A, of which mannitol and especially glucose are the most preferred. [0022]
  • By using this type of starting compounds relatively high molecular weight hard polylactide-co-glycolide materials can be obtained, which are very suitable as implants or microparticle materials, and have 2 or 3, preferably more than 3, e.g. 4 relatively short polylactide-co-glycolide chains and can hydrolyse in the body tissues within a relatively short drug release period of some weeks to e.g. 2 months or more, preferably within 4-6, e.g. 5 weeks. Although according to the invention the purified polylactides can have a linear structure, the preferred purified polylactides according to the invention are those having the structure described in the GB Patent 2.145.422 A, being esters of a polyol containing at least 3 hydroxyl groups, preferably those being an ester of a sugar or a sugar alcohol, especially an ester of glucose. They are star shaped, having a centre of e.g. the glucose rest and rays of linear polylactide chains. [0023]
  • After their preparation the star polymers are, more than the linear polymers, contaminated by brown-coloured by-products, since the sugar or sugar alcohol, used for their preparation, is also be partially decomposed by the catalyst. The star polymers have monomer molar ratios of lactid/glycolide units which are preferably those, indicated above for the linear polymers. [0024]
  • The star polymers have preferably a mean molecule weight M[0025] w of from 10000 to 200000, especially of from 25000 to 100000, particularly of from 35000 to 60000, e.g. about 50000 and preferably have a polydipersity Mw/Mn of from 1.7 to 3.0, especially from 2.0 to 2.5. Poly-lactide-co-glycolides of a linear structure, not being star polymers in a purified state according to the invention have preferably a mean molecular weight Mw of from 25000 to 100000 and have preferably a polydispersity Mw/Mn of from 1.2 to 2.
  • The molecular weight M[0026] w is determined by gelpermeation chromatography, using polystyrene as a standard, e.g. Dupont Ultrastyragel R 1000 or 500 Angstrom, in the column and e.g. tetrahydrofuron as the solvent.
  • The purified polylactides according to the invention can be obtained in a new process by contacting a solution of the impure polylactide with active charcoal and isolating the purified polylactide from the eluate. This process is also a part of the invention. [0027]
  • It is known from the UK Patent 1.467.970 and the EP 0181.621 A2 to treat polymers, produced in the presence of a catalyst with active charcoal. [0028]
  • According to the GB Patent 1.647.970, the polymer is a polyether, obtained from alkylene oxides, like ethylene oxide, propylene oxide or epichlorohydrin with an active hydrogen containing compound, e.g. glycerol, sorbitol or sucrose, in the presence of a basic catalyst. The polymer is purified with a mixture of active charcoal and magnesium silicate to remove crystals of polyalkylene glycols, e.g. polyethylene glycols, formed as by-products and which give the polymers a cloudy appearance and unsatisfactory viscosity and chemical properties. In a preferred method the polyethers are pretreated by means of a not further described other purification method to remove unreacted alkylene oxides and catalyst (page 2, lines 16-20). The basic catalyst thus could clearly not be removed by the charcoal—magnesium silicate mixture. [0029]
  • According to the EP 0181 621 A2 a solution of a polyalkylene ether in a cyclic ether or in a polyhydric alcohol solvent or the polyalkylene ether itself, e.g. polyoxytetramethylene glycol, prepared by the polymerisation of tetrahydrofuran under the influence of a heteropoly acid catalyst, e.g. 12-tungstophosphoric acid, is mixed with an organic hydrocarbon or halogenated hydrocarbon solvent. This solvent, which will contain the greatest part of the heteropoly acid, is separated from the other phase and the residue is contacted for further purification with a solid adsorbent, like charcoal, aluminium oxide or oxides, hydroxides or carbonates of e.g. Mg or Ca or with basic ion-exchange resins. According to Table 2 on page 23, the polymers contain 0.2 to 1.8 ppm of acidic metal contamination after purification with active charcoal. [0030]
  • This purification process is thus used to purify a polyether and to remove a very specific acidic catalyst type and it could not be foreseen, that active charcoal can be used for the removal of cations, like Sn++. Also it could not be foreseen, that such low impurity levels can be obtained as indicated. [0031]
  • The amounts of active charcoal used according to the purification process of the invention are generally from about 10 to 200%, e.g. 70 to 150% of the polymer weight. Any available charcoal can be used, e.g. as described in the Pharmacopoeia. A representative charcoal type is Norit of Clydesdate Co. Ltd., Glasgow/Scotland. [0032]
  • Typically powdered charcoal is used e.g. finely ground charcoal wherein at least 75% passes through a 75 micrometer sieve. Suitable charcoals as used in the Example hereafter, are described in brochures, available from Norit, e.g. “Summary of methods for testing Norit activated carbons on specifications” by J. Visser. [0033]
  • The new purification process with charcoal is especially of interest for star polymers which have a dark brown colour. The colour effect may partly be caused by the polyol, e.g. the glucose, being instable to heat, especially in the presence of a catalyst and is more pronounced than a reference solution of colour strength B[0034] 1.
  • It is believed that the presence of small amounts of acidic groups in the active charcoal are responsible for the surprisingly efficient removal of the cations. If a solution of the catalyst in an organic solvent is treated with charcoal, the catalyst compound is decomposed and the tin is removed with the charcoal, which is filtered of, whereas the anionic part of the catalyst is quantitatively found back in the remaining solution. [0035]
  • For this reason the invention also provides a method for the purification of the polylactide by contacting a solution of the impure polymer with a matrix having on its surface acidic groups and isolating the purified polylactide from the eluate. [0036]
  • If desired a weakly acidic cationic exchanger with a carboxylic acid functionality may be used if it is of an appropriately small particle size. For example, one with a hydrogen ionic form, a density when wet of about 0.69 g/ml (apparent) and 1.25 g/ml (true), a shipping weight of 690 g/liter, an effective particle size of 0.33 to 0.50 mm, a moisture content of 43 to 53 per cent, a pH tolerated range of 5 to 14, a maximum operating temperature of 120° C., a total exchange capacity of 10 meq (dry) and 3.5 meq/ml (wet). An example is Amberlite IRC-50 Methacrylic aci DVB (available from Fluka, Switzerland) which is ground to have the particle size diameter reduced e.g. to below 1 mm or 100 microns. [0037]
  • The matrix for the purification, e.g. the charcoal, preferably has a suitable concentration of from 0.01 o 0.1 millimole of acidic groups per gram of matrix and is conveniently in the form of particles which may be finely divided. Typical particle diameters are e.g. from 1 micrometer to 1 mm, e.g. from 10 to 100 micrometers. [0038]
  • They have therefore a large surface area. For example active charcoal has a surface area of 1000 square meters for each ml of matrix substance. [0039]
  • The purification process of the invention is preferably related to a polylactide preparation using lactide and glycolide as monomers and metal cations, like Sn[0040] ++ as a catalyst, since this polymerisation process gives a better yield and, if desired, a higher molecular weight than the preparation process using lactid acid and glycolic acid as starting compounds and the strong acid ion-exchange resin as a catalyst, described in the European Patent No. 0026599.
  • Starting with an impure polylactide-co-glycolide containing about 1800 ppm of Sn[0041] ++, the concentration of Sn++ can be lowered to about 200 ppm. A purification with charcoal can lower the Sn++ content, as already mentioned, to less than 1.5, e.g. less than 1 ppm.
  • The purification process of the invention is preferably carried out with a solution of an impure polylactide in acetone although other solvents are possible. [0042]
  • The process may be followed by another purification process, preferably the process of ultrafiltration, which reduces the content of low molecular compounds, e.g. of lactide and glycolide. Also in this process a polylactide solution in acetone can be used. [0043]
  • After the second purification process purified polylactides can be obtained, having a monomer content of at most 1% by weight of polymer, preferable of at most 0.25% of polymer, e.g. of at most 0.2% of lactide and 0.05% of glycolide, a water content of at most 1%, an organic solvent, e.g. methylene chloride or acetone, content of at most 1%, preferably of at most 0.5% e.g. of at most 0.3% and an ash content of at most 0.1% by weight of polylactide. Their acid number is preferable at most 10. The thus purified polylactides are preferably parenterally used, e.g. as a matrix for drug compounds, especially such in implants or in microparticles form. These forms may be prepared in conventional manners, which have abundantly been described in the literature e.g. in the European Application No 58481, the UK Patent Application GB 2.145.422, the European Patent Application No 52510 the U.S. Pat. Nos. 4,652,441 and 4,711,782, the French Application No 2.491.351, the U.S. Pat. No. 3,773,919. [0044]
  • The forms are suitable for e.g. incorporating a hydrophilic drug like a peptide, e.g. a cyclopeptide and particularly a hormonally active peptide, like a somatostatin, especially octreotide, or an acid addition salt or a derivative thereof, or a lipophilic drug, like an ergot alkaloid, e.g. bromocriptine. [0045]
  • The pharmaceutical compositions are formed by working up the purified polylactide with the drug compound to form an implantate or a microparticle. [0046]
  • EXAMPLE 1
  • a) Preparation of PLG-Glu [0047]
  • This is prepared as described in the above-mentioned UK Patent Application GB 2.145.422. [0048]
  • [0049]
  • D,L-lactide and glycolide (60/40% by weight) containing trace amounts of lactic and glycolic acid as impurities, are polymerised at 130 ° in the presence of 0.2 per cent (w/w) D (+) glucose and 0.6 per cent (w/w) of tin octanoate (product T9 from M & T Chemicals which is the tin (II) salt of 2-ethyl hexanoic acid; Lemon yellow liquid; Viscosity (20° C.) 1.2636; Refractive Index 1.4950; Tin content 27-29%; 2-ethyl hexanoate content according to NaOH titration 69 per cent). [0050]
  • The product is the polylactide-co-glycolide glucose ester (PLG-Glu) having a lactide/glycolide ratio of 60/40 g (basis) or 55/45 mole (basis). Mw=50000. Lactide/glycolide content ca 3% of weight. The colour is dark brown and is according to the used colour index more intensely coloured than a reference solution B[0051] 1. The tin content is 1800 ppm.
  • b) Treatment with Active Charcoal [0052]
  • 130 g PLG-Glu is dissolved in 1950 ml acetone to give a clear dark brown solution. Within 5 minutes 130 g active charcoal is added. The mixture is stirred for 3 hours at room temperature and filtered. The material filtered off is washed with 1.5 liters of acetone. The filtrate is slightly yellow, of a colour index B[0053] 9. It is evaporated under a vacuum and the residue is dried at 70° C. and finally under a vacuum of 1 mm Hg. Mw=50000; Lactide/glycolide content ca 3%. Heavy metal content: less than 10 ppm.
  • Resultant analysis: Fe 3 ppm; Zn 1 ppm; Cu 1 ppm; Ni, Pb and Sn each under 1 ppm. [0054]
  • The filtered off charcoal contains practically all the tin and the filtrate practically all the 2-ethylhexanoic acid from the catalyst. (If the experiment is repeated with 50 per cent active charcoal by weight of polymer then the product contains 290 ppm Sn). [0055]
  • c) Ultrafiltration [0056]
  • The product from step b) (180 g) is dissolved in 1.8 liters of acetone to give a bright yellow solution. The product is subjected to ultrafiltration using a laboratory pressure filtration apparatus, using acetone (ca. 4×1800 ml) as a solvent under a pressure of 5 bar having a membrane from DDS Type FS 81PP (exclusion limit 6000) diameter 14 cm, with a permeation rate of about 110 to 165 ml/hour. The permeation solution contains lactide/glycolide and lactic and glycolid acid and is coloured yellow. The residual solution in the pressure chamber (2215 ml of solution) is evaporated after a run of 46 hours. The product is taken up again in acetone, filtered and dried at 70 to 80° C. in a vacuum. The product (148 g) contains 0.2% by weight of lactide; 0.05% by weight of glycolide. Acetone content 0.3% by weight. No 2-ethyl hexanoic acid is detecable by gas chromatography (i.e. its content is less than 0.1 per cent). M[0057] w=50000 according to GPC.
  • Accordingly to the colour test laid down in the European Pharmacopoeia 2nd Edition, Section V.6.2 the polymer is “colourless”. The product is not more intensely coloured than the reference solution B[0058] 9.
  • EXAMPLE 2
  • [0059] 4 kg of poly(D,L-lactide-co-glycolide) purified according to the method of Example 1 and having a Mw 55100, were dissolved in 53 kg of methylene chloride.
  • To the filtered solution 1 kg of bromocriptine-mesylate was added. The resulting suspension was intensively mixed by means of an Ultra-Turrax and spray dried. The generated microparticles were sieved, washed with 0.01 molar methane-sulfonic acid/sodium chloride solution and rinsed with isotonic saline. The microparticles were dried under vacuum at 40-45° C. and sieved. The microparticles were filled in glass-vials under nitrogen and sterilized by gamma-irradiation (dose: 25 kGy). [0060]
  • The final product is an aseptically filled two chamber syringe (TCS) consisting of one compartment containing the microparticles and one compartment containing a vehicle for suspension of the microparticles. [0061]
    Vehicle composition:
    mg/ml
    Potassium-dihydrogenphosphate 3.603
    Disodium-hydrogenphosphate (anhydrous) 5.68
    Pluronic F68 2.0
    Sodium-carboxymethylcellulose 10.0
    (Blanose 7LFD)
    Benzylalcohol 10.0
    Water for injections ad 1.0
    ml
    Nitrogen q.s.
  • The TCS are suitable for e.g. i.m. administration, once every 4 weeks. [0062]
  • Results from clinical studies obtained with the TCS in postpartum women, patients with hyperprolactinemia/-microprolactinomas and patients with macroprolactinomas demonstrate a continuous release of active substance and a good systemic and local tolerability as well as good efficacy of single and multiple administrations of bromocriptine-microparticles. [0063]
  • EXAMPLE 3
  • One g of poly (D,L,-lactide-co-glycolide)glucose, M[0064] w 46000, (50/50) molar, (produced according to the process of GB 2.145.422, Polydispersity ca. 1.7, produced from 0.2% of weight glucose and purified according to Example 1) was dissolved in 10 ml of methylene chloride with magnetic stirring followed by the addition of 75 mg of Octreotide dissolved in 0.133 ml of methanol. The mixture was intensively mixed e.g. by means of an Ultra-Turax for one minute at 20,000 rpm causing a suspension of very small crystals of Octreotide in the polymer solution.
  • The suspension was sprayed by means of a high speed turbine (Niro Atomizer) and the small droplets dried in a stream of warm air generating microparticles. The microparticles were collected by a “zyklon” and dryed overnight at room temperature in a vacuum oven. [0065]
  • The microparticles were washed with 1/15 molar acetate buffer pH 4.0 during 5 minutes and dried again at room temperature in a vacuum oven. After 72 hours the microparticles were sieved (0.125 mm mesh size) to obtain the final product. [0066]
  • The microparticles were suspended in a vehicle and administered i.m. in 5 mg/kg dose of Octreotide to white rabbits (chincillabastard) and s.c. in a 10 mg/kg dose to male rats. [0067]
  • Blood samples were taken periodically, indicating plasma levels of 0.3 to 10.0 ng/ml (5 mg dose) in rabbits and 0.5 to 7.0 ng/ml in rats for 42 days as measured by Radioimmunoassay (RIA) analysis. [0068]

Claims (31)

    What we claim is:
  1. 1. A polylactide in a purified state, which meets the requirements of
    the colour strengths of reference solutions B2-B9 of the brown colour test of the European Pharmacopoeia, 2nd Edition (1980) part I, Section V, 6.2 and
    containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm.
  2. 2. A polylactide according to claim 1, having the colour strength of reference solutions B4-B9.
  3. 3. A polylactide according to claim 2, having the colour strength of reference solution B9.
  4. 4. A polylactide according to claim 1, in which the metal ion is Sn++.
  5. 5. A polylactide according to claim 4, having a Sn++ concentration of at most 1.5 ppm.
  6. 6. A polylactide according to claims 4, in which the Sn++ accompanying salt anion is ethyl hexanoate.
  7. 7. A polylactide according to claim 6, having an ethyl hexanoate concentration of at most 0.5% by weight of the polylactide.
  8. 8. A polylactide according to claim 1, having a
    monomer content of at most 1% by weight of the polylactide water content of at most 1% by weight of the polylactide organic solvent content of at most 1% by weight of the polylactide ash content of at most 0.1% by weight of the polylactide and having an acid number of at most 10.
  9. 9. A polylactide according to claim 1, containing additionally glycolide units.
  10. 10. A polylactide according to claim 9, having lactide/glycolide molar ratio's of 100-25/0-75.
  11. 11. A polylactide according to claim 10, having molar rations of 75-25/25-75.
  12. 12. A polylactide according to claim 11, having molar ratio's of 60-40/40-60.
  13. 13. A polylactide according to claim 1, being an ester of a polyol containing at least 3 hydroxyl groups.
  14. 14. A polylactide according to claim 13, being an ester of a sugar or of a sugar alcohol.
  15. 15. A polylactide according to claim 13, being a glucose ester.
  16. 16. A polylactide according to claims 1, being a linear polylactid-glycolide.
  17. 17. A polylactide according to claims 13 having a mean molecular weight Mw of from 10000 to 200000.
  18. 18. A polylactide according to claim 13, having a polydispersity Mw/Mn of from 1.7 to 3.0.
  19. 19. A polylactide according to claim 16, having a mean molecular weight Mw of from 25,000 to 100,000.
  20. 20. A polylactide according to claim 16, having a polydispersity Mw/Mn of from 1.2 to 2.0
  21. 21. A polylactide according to claim 1, obtained by contacting a solution of the impure polylactide with a matrix having on its surface acidic groups.
  22. 22. A method for obtaining the polylactide according to claim 1, by contacting a solution of the impure polylactide with a matrix having on its surface carboxylic groups and isolating the purified polylactide from the eluate.
  23. 23. A method for obtaining the polylactide according to claim 1, by contacting a solution of the impure polylactide with active charcoal and isolating the purified polylactide from the eluate.
  24. 24. A method according to claim 23, in which the isolation includes a further purification step, which is ultrafiltration.
  25. 25. A method according to claim 23 in which the impure polylactide is dissolved in acetone.
  26. 26. A pharmaceutical composition containing a polylactide according to claim 1 as a matrix for a drug compound.
  27. 27. A pharmaceutical composition according to claim 26, comprising bromocriptine as the drug compound.
  28. 28. A pharmaceutical composition according to claim 26, comprising a peptide as the drug compound.
  29. 29. A pharmaceutical composition according to claim 28, comprising a somatostatin as the drug compound.
  30. 30. A pharmaceutical composition according to claim 29, comprising octreotide or an acid addition salt or a derivative therof.
  31. 31. Process for the preparation of the pharmaceutical composition of claim 26, which comprises working up the polylactide of claim 1 with the drug compound to form an implantate or a microparticle.
US10054490 1990-08-01 2002-01-22 Organic compounds Abandoned US20020098238A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB9016840A GB9016840D0 (en) 1990-08-01 1990-08-01 Improvements in or relating to organic compounds
GB9016840 1990-08-01
GB9016882A GB9016882D0 (en) 1990-08-01 1990-08-01 Improvements in or relating to organic compounds
GB9016882 1990-08-01
US73796091 true 1991-07-30 1991-07-30
US12167493 true 1993-09-15 1993-09-15
US35346794 true 1994-12-09 1994-12-09
US47105395 true 1995-06-06 1995-06-06
US09089836 US6353030B1 (en) 1990-08-01 1998-06-03 Relating to organic compounds
US10054490 US20020098238A1 (en) 1990-08-01 2002-01-22 Organic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10054490 US20020098238A1 (en) 1990-08-01 2002-01-22 Organic compounds
US10922432 US20050025835A1 (en) 1990-08-01 2004-08-19 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09089836 Continuation US6353030B1 (en) 1990-08-01 1998-06-03 Relating to organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10922432 Division US20050025835A1 (en) 1990-08-01 2004-08-19 Organic compounds

Publications (1)

Publication Number Publication Date
US20020098238A1 true true US20020098238A1 (en) 2002-07-25

Family

ID=27516985

Family Applications (3)

Application Number Title Priority Date Filing Date
US09089836 Expired - Fee Related US6353030B1 (en) 1990-08-01 1998-06-03 Relating to organic compounds
US10054490 Abandoned US20020098238A1 (en) 1990-08-01 2002-01-22 Organic compounds
US10922432 Abandoned US20050025835A1 (en) 1990-08-01 2004-08-19 Organic compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09089836 Expired - Fee Related US6353030B1 (en) 1990-08-01 1998-06-03 Relating to organic compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10922432 Abandoned US20050025835A1 (en) 1990-08-01 2004-08-19 Organic compounds

Country Status (1)

Country Link
US (3) US6353030B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292195A1 (en) * 2007-02-15 2010-11-18 Qlt Usa, Inc. Low burst polymers and methods to produce polymer
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256241B2 (en) * 2000-01-21 2007-08-14 Cyclics Corporation Methods for polymerizing macrocyclic polyester oligomers using catalyst promoters
US7151143B2 (en) * 2000-01-21 2006-12-19 Cyclics Corporation Blends containing macrocyclic polyester oligomer and high molecular weight polymer
US6960626B2 (en) * 2000-01-21 2005-11-01 Cyclics Corporation Intimate physical mixtures containing macrocyclic polyester oligomer and filler
US20050282952A1 (en) * 2000-01-21 2005-12-22 Cyclics Corporation Graphite-polyester composites made from macrocyclic polyester oligomers
US6420047B2 (en) * 2000-01-21 2002-07-16 Cyclics Corporation Macrocyclic polyester oligomers and processes for polymerizing the same
US7750109B2 (en) 2000-09-01 2010-07-06 Cyclics Corporation Use of a residual oligomer recyclate in the production of macrocyclic polyester oligomer
US7767781B2 (en) * 2000-09-01 2010-08-03 Cyclics Corporation Preparation of low-acid polyalkylene terephthalate and preparation of macrocyclic polyester oligomer therefrom
DE60121602T2 (en) * 2000-09-01 2007-07-05 Cyclics Corp. oligoesterzusammensetzungen to macrocyclic method for converting linear polyesters and macrocyclic oligoester
US7304123B2 (en) * 2001-06-27 2007-12-04 Cyclics Corporation Processes for shaping macrocyclic oligoesters
ES2250687T3 (en) 2001-06-27 2006-04-16 Cyclics Corporation Isolation, formulation, and shaping macrocyclic oligoesters.
US6831138B2 (en) * 2002-01-07 2004-12-14 Cyclics Corporation Polymer-containing organo-metal catalysts
US6906147B2 (en) * 2002-03-20 2005-06-14 Cyclics Corporation Catalytic systems
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
WO2004058854A1 (en) * 2002-12-20 2004-07-15 Cyclics Corporation Purification of macrocyclic oligoesters
DE602004025971D1 (en) * 2003-12-19 2010-04-22 Cyclics Corp A method for dispersing an impact modifier in a macrocyclic polyester oligomer
US20080303360A1 (en) * 2007-06-11 2008-12-11 Hewlett-Packard Development Company L.P. Insulated bearing motor assembly
US8853351B2 (en) * 2007-12-31 2014-10-07 Samyang Biopharmaceuticals Corporation Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof
EP2583990B9 (en) * 2010-06-21 2017-11-15 LG Chem, Ltd. Outstandingly heat resistant polylactide resin and a production method for the same

Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2703316A (en) * 1951-06-05 1955-03-01 Du Pont Polymers of high melting lactide
US3169945A (en) * 1956-04-13 1965-02-16 Union Carbide Corp Lactone polyesters
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3963699A (en) * 1974-01-10 1976-06-15 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
US4033938A (en) * 1974-01-21 1977-07-05 American Cyanamid Company Polymers of unsymmetrically substituted 1,4-dioxane-2,5-diones
US4104464A (en) * 1975-04-18 1978-08-01 Tate & Lyle Limited Purification of sucrose esters
US4130639A (en) * 1977-09-28 1978-12-19 Ethicon, Inc. Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
US4165432A (en) * 1977-10-18 1979-08-21 Olin Corporation Peroxy di-ester polyols
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4243775A (en) * 1978-11-13 1981-01-06 American Cyanamid Company Synthetic polyester surgical articles
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
US4334061A (en) * 1979-10-29 1982-06-08 Ethyl Corporation Process for recovery of polyol fatty acid polyesters
US4379138A (en) * 1981-12-28 1983-04-05 Research Triangle Institute Biodegradable polymers of lactones
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US4451452A (en) * 1980-11-29 1984-05-29 Sandoz Ltd. Pharmaceutical compositions containing biodegradable polymers
US4452973A (en) * 1982-11-12 1984-06-05 American Cyanamid Company Poly(glycolic acid)/poly(oxyethylene) triblock copolymers and method of manufacturing the same
US4526938A (en) * 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations
US4529736A (en) * 1982-07-28 1985-07-16 American Cyanamid Company 3a-(Substituted phenyl)-2,3,3a,4,7,7a-hexahydro[or 3a-(substituted-phenyl)octahydro]-4,7-alkano-1H-isoindoles for treating depression in warm-blooded animals
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4677231A (en) * 1984-11-13 1987-06-30 Asahi Kasei Kogyo Kabushiki Kaisha Process for purification of polyether
US4677191A (en) * 1984-07-06 1987-06-30 Wada Pure Chemical Ind., Ltd. Copolymer and method for producing the same
US4756907A (en) * 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4810775A (en) * 1987-03-19 1989-03-07 Boehringer Ingelheim Kg Process for purifying resorbable polyesters
US4874612A (en) * 1987-02-12 1989-10-17 Hoechst Aktiengesellschaft Multi-component long-acting medicament formulation for implantation
US4879402A (en) * 1986-07-25 1989-11-07 Bayer Aktiengesellschaft (Methyl)acrylic acid derivatives containing urethane groups
US4891263A (en) * 1987-12-17 1990-01-02 Allied-Signal Inc. Polycarbonate random copolymer-based fiber compositions and method of melt-spinning same and device
US4920203A (en) * 1987-12-17 1990-04-24 Allied-Signal Inc. Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US4960866A (en) * 1986-12-06 1990-10-02 Boehringer Ingelheim Zentrale Catalyst-free resorbable homopolymers and copolymers
US4983745A (en) * 1987-06-16 1991-01-08 Boehringer Ingelheim Kg Meso-lactide, processes for preparing it and polymers and copolymers produced therefrom
US5041529A (en) * 1988-11-07 1991-08-20 Mitsui Toatsu Chemicals, Inc. Preparation process for bioabsorbable polyester
US5053485A (en) * 1987-10-28 1991-10-01 C.C.A. Biochem B.V. Polymer lactide, method for preparing it and a composition containing it
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5585460A (en) * 1990-04-13 1996-12-17 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5922338A (en) * 1983-08-26 1999-07-13 Novartis Ag Polyol esters, their preparation and use in depot forms of pharmacologically active agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US814334A (en) * 1905-03-27 1906-03-06 Continental Can Co Process of recovering tin or tin and lead.
US2210639A (en) * 1938-10-01 1940-08-06 Dow Chemical Co Treatment of monomeric styrene
GB1332505A (en) 1970-10-16 1973-10-03 Ethicon Inc Sutures and other surgical aids
US3933071A (en) 1975-03-27 1976-01-20 Onondaga Tool Corporation Shearproof punch
CA1123984A (en) 1977-11-16 1982-05-18 Yuzi Okuzumi Block copolymers of lactide and glycolide and surgical prosthesis therefrom
DE3021736A1 (en) 1979-06-11 1980-12-18 Syntex Inc New peptide, process for their preparation and containing the same drug
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
EP0052510B2 (en) 1980-11-18 1994-10-19 Syntex (U.S.A.) Inc. Microencapsulation of water soluble polypeptides
DE3273501D1 (en) 1981-02-16 1986-11-06 Ici Plc Continuous release pharmaceutical compositions

Patent Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2703316A (en) * 1951-06-05 1955-03-01 Du Pont Polymers of high melting lactide
US3169945A (en) * 1956-04-13 1965-02-16 Union Carbide Corp Lactone polyesters
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US3963699A (en) * 1974-01-10 1976-06-15 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters
US4033938A (en) * 1974-01-21 1977-07-05 American Cyanamid Company Polymers of unsymmetrically substituted 1,4-dioxane-2,5-diones
US4104464A (en) * 1975-04-18 1978-08-01 Tate & Lyle Limited Purification of sucrose esters
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
US4130639A (en) * 1977-09-28 1978-12-19 Ethicon, Inc. Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
US4165432A (en) * 1977-10-18 1979-08-21 Olin Corporation Peroxy di-ester polyols
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4756907A (en) * 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4243775A (en) * 1978-11-13 1981-01-06 American Cyanamid Company Synthetic polyester surgical articles
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
US4334061A (en) * 1979-10-29 1982-06-08 Ethyl Corporation Process for recovery of polyol fatty acid polyesters
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4451452A (en) * 1980-11-29 1984-05-29 Sandoz Ltd. Pharmaceutical compositions containing biodegradable polymers
US4379138A (en) * 1981-12-28 1983-04-05 Research Triangle Institute Biodegradable polymers of lactones
US4526938A (en) * 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations
US4529736A (en) * 1982-07-28 1985-07-16 American Cyanamid Company 3a-(Substituted phenyl)-2,3,3a,4,7,7a-hexahydro[or 3a-(substituted-phenyl)octahydro]-4,7-alkano-1H-isoindoles for treating depression in warm-blooded animals
US4452973A (en) * 1982-11-12 1984-06-05 American Cyanamid Company Poly(glycolic acid)/poly(oxyethylene) triblock copolymers and method of manufacturing the same
US5922338A (en) * 1983-08-26 1999-07-13 Novartis Ag Polyol esters, their preparation and use in depot forms of pharmacologically active agents
US4677191A (en) * 1984-07-06 1987-06-30 Wada Pure Chemical Ind., Ltd. Copolymer and method for producing the same
US4683288A (en) * 1984-07-06 1987-07-28 Waco Pure Chemical Ind. Inc. Polymer and its production
US4677231A (en) * 1984-11-13 1987-06-30 Asahi Kasei Kogyo Kabushiki Kaisha Process for purification of polyether
US4879402A (en) * 1986-07-25 1989-11-07 Bayer Aktiengesellschaft (Methyl)acrylic acid derivatives containing urethane groups
US4960866A (en) * 1986-12-06 1990-10-02 Boehringer Ingelheim Zentrale Catalyst-free resorbable homopolymers and copolymers
US4874612A (en) * 1987-02-12 1989-10-17 Hoechst Aktiengesellschaft Multi-component long-acting medicament formulation for implantation
US4810775A (en) * 1987-03-19 1989-03-07 Boehringer Ingelheim Kg Process for purifying resorbable polyesters
US4983745A (en) * 1987-06-16 1991-01-08 Boehringer Ingelheim Kg Meso-lactide, processes for preparing it and polymers and copolymers produced therefrom
US5053485A (en) * 1987-10-28 1991-10-01 C.C.A. Biochem B.V. Polymer lactide, method for preparing it and a composition containing it
US4891263A (en) * 1987-12-17 1990-01-02 Allied-Signal Inc. Polycarbonate random copolymer-based fiber compositions and method of melt-spinning same and device
US4920203A (en) * 1987-12-17 1990-04-24 Allied-Signal Inc. Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5041529A (en) * 1988-11-07 1991-08-20 Mitsui Toatsu Chemicals, Inc. Preparation process for bioabsorbable polyester
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5585460A (en) * 1990-04-13 1996-12-17 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292195A1 (en) * 2007-02-15 2010-11-18 Qlt Usa, Inc. Low burst polymers and methods to produce polymer
US9974824B2 (en) 2007-02-15 2018-05-22 Tolmar Therapeutics, Inc. Low-burst polymers and methods to produce polymer
US9187593B2 (en) * 2007-02-15 2015-11-17 Tolmar Therapeutics, Inc. Low burst polymers and methods to produce polymer
US20160106847A1 (en) * 2007-02-15 2016-04-21 Tolmar Therapeutics, Inc. Low-burst polymers and methods to produce polymer
US9561282B2 (en) * 2007-02-15 2017-02-07 Tolmar Therapeutics, Inc. Low-burst polymers and methods to produce polymer
US20170095560A1 (en) * 2007-02-15 2017-04-06 Tolmar Therapeutics, Inc. Low-burst polymers and methods to produce polymers
US9655970B2 (en) * 2007-02-15 2017-05-23 Tolmar Therapeutics, Inc. Low-burst polymers and methods to produce polymers
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same

Also Published As

Publication number Publication date Type
US20050025835A1 (en) 2005-02-03 application
US6353030B1 (en) 2002-03-05 grant

Similar Documents

Publication Publication Date Title
Vert et al. Something new in the field of PLA/GA bioresorbable polymers?
Zhao et al. Polyphosphoesters in drug and gene delivery
US5631015A (en) Liquid absorbable copolymers for parenteral applications
Xu et al. BCNU-loaded PEG–PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells
Li Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids
US5736161A (en) Pharmaceutical preparation for improving the bioavailability of drugs which are difficult to absorb and a procedure for obtaining it
Hickey et al. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices
US6034175A (en) Salts of peptides with carboxy-terminated polyesters
US7122615B1 (en) Polyanhydrides with therapeutically useful degradation products
US6589548B1 (en) Controlled drug delivery system using the conjugation of drug to biodegradable polyester
Eliaz et al. Characterization of a polymeric PLGA‐injectable implant delivery system for the controlled release of proteins
US3755558A (en) Polylactide drug mixtures for topical application atelet aggregation
Visscher et al. Biodegradation of and tissue reaction to poly (DL‐lactide) microcapsules
US5849859A (en) Polyesters
US5942253A (en) Prolonged release of GM-CSF
Mehta et al. Biodegradable microspheres as depot system for patenteral delivery of peptide drugs
US6365173B1 (en) Stereocomplex polymeric carriers for drug delivery
US5662938A (en) Bioresorbable-polymer microspheres of hydroxy acid polymer free from surfactant, their preparation and their application as a drug
US20070155906A1 (en) Biodegradable multi-block co-polymers
Zhang et al. Effects of metal salts on poly (DL‐lactide‐co‐glycolide) polymer hydrolysis
WO1997041837A2 (en) Microparticles
US5683723A (en) Nanoparticles based on a polyoxyethelene and polyactic acid block copolymer
US6599519B1 (en) Biodegradable poly(alkylene oxide)-poly(p-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same
Li et al. Hydrolytic degradation of poly (DL-lactic acid) in the presence of caffeine base
GB2234896A (en) Delayed release formulations